BMJ1d
Interface between valve disease and ischaemic heart disease
Dr Bernard Iung, Cardiology Department, Bichat Hospital, 46, rue Henri Huchard, 75018 Paris, France email: bernard.iung{at}bch.ap-hop-paris.fr If you wish to reuse ...
BMJ4d
Impact of the COVID-19 pandemic on incidence of coronary heart disease in Bavaria, Germany: an analysis of health claims data
Background Inconsistent findings about the impact of the COVID-19 pandemic on cardiovascular disease diagnosis and ...
BMJ6d
Mental disorders and cardiovascular disease: what should we be looking out for?
Correspondence to Dr Matthias Michal, Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz 55131, Germany; ...
BMJ6d
Successful transcatheter aortic valve implantation (TAVI) is associated with transient left ventricular dysfunction
King's College London BHF Centre of Excellence, Department of Cardiology, King's College Hospital, London, UK Correspondence to Dr Philip MacCarthy, Consultant Cardiologist, Department of Cardiology, ...
BMJ10d
Timing of intervention in aortic stenosis: a review of current and future strategies
Correspondence to Dr Russell James Everett, BHF/Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4SB, UK; russell.everett{at}ed.ac.uk To review the pathophysiology of ...
BMJ10d
Optimising management of moderate secondary mitral regurgitation: insights into pharmacological and interventional approaches
Secondary mitral regurgitation (SMR) is a complex and evolving challenge in the landscape of heart failure (HF) management. Although significant secondary MR has been widely recognised for its adverse ...
BMJ10d
Atrial arrhythmia and heart failure in adult patients with congenital heart disease: a retrospective cohort study
Background Atrial arrhythmias (AA) and heart failure (HF) are major causes of hospitalisation in adult congenital heart disease (ACHD). This study aimed to evaluate the temporal relationship between ...
BMJ12d
Excessive daytime sleepiness: an emerging marker of cardiovascular risk
Excessive daytime sleepiness (EDS) is classically viewed as a consequence of insufficient sleep or a symptom of sleep disorders. Epidemiological and clinical evidence have shown that patients ...
BMJ15d
Change in renal function associated with drug treatment in heart failure: national guidance
Inhibitors of the renin–angiotensin–aldosterone (RAAS) system are cornerstones of the management of patients with heart failure with reduced left ventricular ejection fraction (HFrEF). However, RAAS ...
BMJ16d
Automated oxygen administration versus manual control in acute cardiovascular care: a randomised controlled trial
Background Oxygen therapy is commonly administered to patients with acute cardiovascular conditions during hospitalisation. Both hypoxaemia and hyperoxia can cause harm, making it essential to ...
BMJ16d
Association of innate versus specific immunity with heart failure incidence: a prospective study
Background Immune disorders are key heart failure (HF) triggers, but little is known about whether the status of immunity affects the incidence of HF. To explore this, we used blood cell counts and ...
BMJ19d
Evolving use and clinical outcomes of coronary intravascular lithotripsy: insights from an international, multicentre registry
Background Intravascular lithotripsy (IVL) is increasingly used for treatment of coronary artery calcification. This study aimed to evaluate contemporary utilisation patterns, safety and efficacy of ...